Blueprint Medicines has filed a patent for a crystalline solid form of Compound (I) or a pharmaceutically acceptable salt thereof. The compound has the potential to be prepared in various crystalline solid forms and salt forms. GlobalData’s report on Blueprint Medicines gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Blueprint Medicines, Cancer treatment biomarkers was a key innovation area identified from patents. Blueprint Medicines's grant share as of September 2023 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Crystalline solid form of compound (i) or its salt
A recently filed patent (Publication Number: US20230295121A1) describes various crystalline solid forms and pharmaceutically acceptable salts of a compound referred to as Compound (I). The patent claims cover different solid forms of Compound (I) and its salts, as well as their characteristic properties and methods of preparation.
The patent claims include a crystalline solid form of Compound (I) or a pharmaceutically acceptable salt thereof, specifically mentioning the free base of Compound (I). It also claims various pharmaceutically acceptable salts of Compound (I), including salts with benzenesulfonic acid, methanesulfonic acid, hydrochloric acid, hydrobromic acid, and nitric acid. Additionally, the claims describe salts of Compound (I) with counter ions such as pyruvic acid, citric acid, fumaric acid, hydrochloric acid, saccharin, gentisic acid, maleic acid, oxalic acid, salicylic acid, glutaric acid, sulfuric acid, tartaric acid, phosphoric acid, and succinic acid.
The patent claims further specify solid forms of Compound (I) or its salts that exhibit characteristic X-ray powder diffraction (XRPD) patterns, with specific diffraction peaks expressed in degrees 2-theta. These solid forms are also characterized by their XRPD patterns, which include additional diffractions at specific angles.
The claims also mention solid forms of Compound (I) or its salts that exhibit specific thermal properties, such as a differential scanning calorimetry (DSC) thermogram with an endothermic event observed at about 205°C and a reversible mass change of about 10% by DVS between 2-95% relative humidity.
Furthermore, the patent claims describe specific solid forms of Compound (I) or its salts, such as Solid Form A, Solid Form B, Solid Form C, and Solid Form 5-A, among others. These solid forms are characterized by their XRPD patterns and may be obtained through various processes, including slurrying in alcohols, acetone, or ACN, evaporative crystallization and cooling crystallization in IPA and 1-propanol, and recrystallization in acetone:water.
Overall, the patent claims cover a range of crystalline solid forms and pharmaceutically acceptable salts of Compound (I), along with their characteristic properties and methods of preparation. These claims provide valuable information for researchers and pharmaceutical companies interested in developing and utilizing Compound (I) for various applications.
To know more about GlobalData’s detailed insights on Blueprint Medicines, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
